These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21931877)

  • 1. Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro.
    Michel G; Ferrua B; Lang T; Maddugoda MP; Munro P; Pomares C; Lemichez E; Marty P
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1323. PubMed ID: 21931877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
    Valdivieso E; Mejías F; Carrillo E; Sánchez C; Moreno J
    Int J Antimicrob Agents; 2018 Nov; 52(5):682-687. PubMed ID: 29969693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
    Álvarez-Velilla R; Gutiérrez-Corbo MDC; Punzón C; Pérez-Pertejo MY; Balaña-Fouce R; Fresno M; Reguera RM
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007133. PubMed ID: 30763330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
    Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
    Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of the
    Kurt Ö; Mansur Özen N; Aydın EM; Kaya DE; Kayhan CK; Öktem Okullu S; İnce Ü; Yıldız Zeyrek F
    Turkiye Parazitol Derg; 2021 Jun; 45(2):95-100. PubMed ID: 34103284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
    Coelho AC; Oliveira JC; Espada CR; Reimão JQ; Trinconi CT; Uliana SR
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004660. PubMed ID: 27144739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
    Bhattacharya A; Ouellette M
    EBioMedicine; 2018 Nov; 37():13-14. PubMed ID: 30314891
    [No Abstract]   [Full Text] [Related]  

  • 10. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
    Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
    J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miltefosine enhances the fitness of a non-virulent drug-resistant Leishmania infantum strain.
    Eberhardt E; Bulté D; Van Bockstal L; Van den Kerkhof M; Cos P; Delputte P; Hendrickx S; Maes L; Caljon G
    J Antimicrob Chemother; 2019 Feb; 74(2):395-406. PubMed ID: 30412253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron overload favors the elimination of Leishmania infantum from mouse tissues through interaction with reactive oxygen and nitrogen species.
    Vale-Costa S; Gomes-Pereira S; Teixeira CM; Rosa G; Rodrigues PN; Tomás A; Appelberg R; Gomes MS
    PLoS Negl Trop Dis; 2013; 7(2):e2061. PubMed ID: 23459556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum.
    Lage PS; Chávez-Fumagalli MA; Mesquita JT; Mata LM; Fernandes SO; Cardoso VN; Soto M; Tavares CA; Leite JP; Tempone AG; Coelho EA
    Parasitol Res; 2015 Dec; 114(12):4625-35. PubMed ID: 26346453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miltefosine-Lopinavir Combination Therapy Against
    Rebello KM; Andrade-Neto VV; Gomes CRB; de Souza MVN; Branquinha MH; Santos ALS; Torres-Santos EC; d'Avila-Levy CM
    Front Cell Infect Microbiol; 2019; 9():229. PubMed ID: 31316919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection.
    Van Bockstal L; Bulté D; Hendrickx S; Sadlova J; Volf P; Maes L; Caljon G
    Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():16-21. PubMed ID: 32388220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.
    Cunha-Júnior EF; Andrade-Neto VV; Lima ML; da Costa-Silva TA; Galisteo Junior AJ; Abengózar MA; Barbas C; Rivas L; Almeida-Amaral EE; Tempone AG; Torres-Santos EC
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005281. PubMed ID: 28045892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
    Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of transgenic Leishmania infantum expressing mLLO-BAX-SMAC in the apoptosis of the infected macrophages in vitro and in vivo.
    Aghaei M; Khanahmad H; Aghaei S; Hosseini SM; Farahmand M; Hejazi SH
    Parasite Immunol; 2020 Nov; 42(11):e12726. PubMed ID: 32367588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.